Highest-materiality recent filing
Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns
Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.
Arcutis appoints Christopher Peetz to Board of Directors
Christopher Peetz appointed as Class III director effective July 15, 2026; term expires at 2029 annual meeting.
Shareholders approve all proposals; board adopts updated director compensation program
Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M
Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.
Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M
Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).
Arcutis appoints Amit Munshi to Board; founder Chaudhuri retires, retains consulting role
Bhaskar Chaudhuri retired from Board and Compensation Committee chair on Dec 3, 2025; no disagreement.
Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M
Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.
Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis
Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.
Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).
Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO
Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.
Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025
Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.
Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M
Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.
Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)
Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.
Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M
ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.
Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M
ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.
Arcutis stockholders elect three directors, ratify EY, approve say-on-pay at 2024 annual meeting
All three Class I director nominees elected: Terrie Curran (77.2M for), Halley Gilbert (75.8M for), Keith R. Leonard Jr. (59.3M for).
Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M
Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.
Arcutis appoints David Topper as CFO, replacing interim CFO John Smither
David Topper named CFO effective April 10, 2024; John Smither steps down and resigns April 30.
Arcutis raises ~$161.6M in public offering of 18.2M shares at $9.50
Issued ~18.2M shares at $9.50 via underwritten public offering, raising ~$161.6M net.
Arcutis licenses ZORYVE to Sato for Japan; $25M upfront, up to $65M milestones
Upfront payment of $25M; up to $10M in regulatory milestones and $30M in sales milestones.
Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched
Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.
Arcutis completes stock option exchange; 98% of eligible options surrendered for 2.13M new RSUs
Options to purchase 5.06M shares surrendered (~98% of eligible); 2.13M new RSUs issued.
Arcutis announces voluntary option exchange program for underwater stock options
Eligible employees/consultants can exchange options with exercise price >=$10.00 for fewer RSUs.
FDA approves Arcutis' ZORYVE foam for seborrheic dermatitis in ages 9+
ZORYVE (roflumilast) topical foam 0.3% approved by FDA for seborrheic dermatitis.
Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M
Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.
Offering: 32.5M common shares at $2.50 each plus pre-funded warrants for 7.5M shares at $2.4999 each.
Arcutis pre-announces Q3 revenue of $38.1M; ZORYVE approved for pediatric psoriasis
Preliminary Q3 2023 total revenue of $38.1M: $8.1M net product revenue (ZORYVE) and $30M other revenue from Huadong Medicine license.
Arcutis appoints L. Todd Edwards as Chief Commercial Officer; Ayisha Jeter promoted
Edwards joins from Incyte with 25+ years in dermatology/immunology at UCB and AbbVie.
Arcutis appoints John Smither as interim CFO with $550K salary, option grant of 125K shares at $8.54
Base salary of $550,000 and target annual bonus of 45% of base salary.
Arcutis CFO Scott Burrows resigns; former CFO John Smither named interim CFO
Scott Burrows resigns as CFO effective Aug 31, 2023 to pursue external opportunity; no disagreement with company.
Arcutis Biotherapeutics signs license deal with Huadong for ZORYVE in Asia, receiving $30M upfront
Arcutis grants exclusive license to Huadong for ZORYVE cream and ARQ-154 foam in Greater China and Southeast Asia.
Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M
Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.
All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).
Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO
Ken Lock, SVP and CCO since Oct 2019, resigns effective June 2, 2023 to attend to personal matters.
Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds
Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.
Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter
Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.
Arcutis reports positive Phase 3 results for roflumilast cream 0.15% in atopic dermatitis
INTEGUMENT-1: 32.0% of roflumilast patients achieved IGA success vs 15.2% vehicle (p<0.0001); INTEGUMENT-2: 28.9% vs 12.0% (p<0.0001).
Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue
Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.
Arcutis acquires Ducentis for ~$30M upfront; DS-234 for atopic dermatitis
Upfront consideration ~$30M (~$16M cash + ~$14M in stock); contingent milestones up to ~$400M.
Arcutis appoints Neha Krishnamohan to Board of Directors and audit committee
Board expanded from 9 to 10; Krishnamohan appointed Class III director and audit committee member.
Sold 7.5M shares plus full exercise of over-allotment of 1.125M shares at $20 per share.
Arcutis reports Q2 net loss $67.4M; FDA approved ZORYVE for plaque psoriasis
FDA approved ZORYVE (roflumilast cream) for plaque psoriasis in patients 12+; launch expected in coming weeks.
FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.
80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)
Arcutis stockholders elect all three Class II directors and ratify Ernst & Young
Bhaskar Chaudhuri received 39.76M votes for, 3.83M withheld; Howard Welgus 30.92M for, 12.66M withheld; Sue-Jean Lin 39.09M for, 4.49M withheld.
Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29
Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.
Arcutis reports Q4 2021 net loss of $71.3M, cash $388.6M; FDA accepted NDA for roflumilast cream
Net loss of $71.3M ($1.42 per share) for Q4 2021 vs $34.0M ($0.79) in Q4 2020.
$75M drawn at closing; additional $125M available upon FDA approval of roflumilast cream for plaque psoriasis; $25M upon revenue milestones.
Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis
Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.
Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis
Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.
has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.
On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.
Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.
On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.
On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
On September 27, 2023, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) announced the appointment of L. Todd Edwards as the Company’s Chief Commercial Officer, effective as of September 27, 2023.
In connection with the appointment of Mr. Edwards, Ms. Jeter will be promoted to Senior Vice President, Marketing and Market Access, effective as of September 27, 2023.
announcing the appointment of John Smither as the Company’s interim chief financial officer, effective as of August 31, 2023
On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.
The Company has commenced a search for a permanent chief financial officer and has appointed John Smither, who previously served as the Company’s chief financial officer from May 2019 until his retirement in March 2021, as interim chief financial officer, effective upon Mr. Burrows’ departure from the Company on August 31, 2023.
Max materiality 0.90 · Median 0.70 · Most common event earnings